Ignite Creation Date:
2025-12-25 @ 3:25 AM
Ignite Modification Date:
2026-01-01 @ 3:56 AM
Study NCT ID:
NCT00907205
Status:
COMPLETED
Last Update Posted:
2013-06-13
First Post:
2009-05-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
Sponsor:
Semafore Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-04
Start Date Type:
None
Primary Completion Date:
2011-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-04
Completion Date Type:
ACTUAL
First Submit Date:
2009-05-20
First Submit QC Date:
None
Study First Post Date:
2009-05-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-06-11
Last Update Post Date:
2013-06-13
Last Update Post Date Type:
ESTIMATED